Key Points
- CEO Abraham Ceesay sold 18,921 shares of Rapport Therapeutics at an average price of $49.57, generating approximately $937,914. He retains 467,187 shares, and the sale reduced his ownership by 3.89%.
- Rapport shares opened at $52.50, near their 52-week high of $52.83, with a market capitalization of approximately $2.52 billion. The company recently reported a quarterly loss of $1.19 per share, missing the consensus estimate of a $1.12 loss.
- Analysts remain broadly positive, with the stock carrying a consensus “Buy” rating and an average price target of $62.86; recent targets range from $65 to $75.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 18,921 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $49.57, for a total value of $937,913.97. Following the completion of the sale, the chief executive officer owned 467,187 shares in the company, valued at $23,158,459.59. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Abraham Ceesay also recently made the following trade(s):
- On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58.
- On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The stock was sold at an average price of $46.26, for a total transaction of $1,042,746.66.
- On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The stock was sold at an average price of $42.11, for a total transaction of $93,063.10.
Rapport Therapeutics Stock Performance
Shares of NASDAQ RAPP opened at $52.50 on Thursday. The company's 50 day moving average price is $42.90 and its 200-day moving average price is $36.62. Rapport Therapeutics, Inc. has a 52-week low of $14.11 and a 52-week high of $52.83. The company has a market capitalization of $2.52 billion, a P/E ratio of -17.27 and a beta of 0.97.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts have weighed in on the company. Raymond James Financial reiterated a "strong-buy" rating and set a $75.00 price target on shares of Rapport Therapeutics in a report on Monday, August 17th. BTIG Research reissued a "buy" rating and issued a $65.00 price objective on shares of Rapport Therapeutics in a research note on Wednesday, August 19th. HC Wainwright upped their target price on Rapport Therapeutics from $40.00 to $66.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. William Blair initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating for the company. Finally, Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $62.86.
Get Our Latest Stock Report on RAPP
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Johnson & Johnson bought a new position in shares of Rapport Therapeutics during the 2nd quarter worth about $74,360,823,000. Swedbank AB bought a new stake in Rapport Therapeutics in the 4th quarter valued at about $3,434,000. Walleye Capital LLC bought a new stake in Rapport Therapeutics in the 2nd quarter valued at about $4,257,000. Dimensional Fund Advisors LP raised its stake in Rapport Therapeutics by 168.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 224,498 shares of the company's stock worth $7,025,000 after buying an additional 141,011 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Rapport Therapeutics by 23.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company's stock worth $91,077,000 after buying an additional 579,903 shares during the period.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
